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Abstract
Background: Dogs can suffer from inappetence caused by a variety of medical conditions. This may present as anorexia
(complete loss of appetite), hyporexia (decreased appetite) or dysrexia (change in food preferences). A drug with a new
mechanism of action, capromorelin, has potential to stimulate appetite in dogs. Capromorelin is a ghrelin receptor
agonist, which mimics the action of endogenous ghrelin. It is a member of the growth hormone secretagogue
(GHS) class of drugs. Capromorelin oral solution (ENTYCE®) was tested in healthy adult male and female Beagle
dogs (n = 6 males and 6 females per group) for its effect on food consumption and body weight. A randomized,
masked, placebo controlled study was conducted to measure the effects of a daily 3 mg/kg oral dose given over
4 days. Dogs were observed for clinical signs, physical examinations were completed prior to and at the end of treatment,
and blood was drawn before and after treatment for evaluation of serum chemistry and hematology parameters.
Results: Capromorelin was well-tolerated, with no abnormalities seen on physical examination or clinical
pathology. Some dogs showed increased salivation. Capromorelin treated dogs had increased mean (±SD)
food consumption compared to placebo treated dogs (60.55 ± 39.87% versus -11.15 ± 14.23% respectively, P < 0.001).
Treated dogs also had increased mean body weights compared to placebo treated dogs (5.96 ± 1.76% versus
0.053 ± 1.14% respectively, P < 0.001).
Conclusions: This study supports the effectiveness of capromorelin oral solution as an appetite stimulant in dogs.
Treatment with the oral solution resulted in dramatic increases in appetite, as measured by food consumption, of
over 60% compared to placebo. The drug was well tolerated. Capromorelin is the first ghrelin receptor agonist developed
for appetite stimulation in any species, and represents a novel mechanism of action for this clinical use.
Keywords: Ghrelin receptor agonist, Growth hormone secretagogue, Anorexia, Appetite stimulation
* Correspondence: eheinen@aratana.com
3Aratana Therapeutics, Inc., 11400 Tomahawk Creek Parkway, Suite 340,
Leawood, KS, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zollers et al. BMC Veterinary Research  (2017) 13:10 
DOI 10.1186/s12917-016-0925-z
Background
Dogs can present at the veterinary clinic with anorexia
(a complete lack of eating), hyporexia (a decrease in food
intake) or dysrexia (altered preferences or patterns of
eating). Reduced appetite (inappetence) is a common,
nonspecific clinical sign in dogs that is associated with
many diseases. Owners may notice a reduced or changed
appetite as the first indication that something may be
wrong with their dog’s health. Reduced food intake con-
tributes to weight and muscle loss and can cause signifi-
cant nutritional deficiencies, which can further exacerbate
many medical conditions and may even have direct nega-
tive effects [1, 2]. Owners can become distressed when
their dog does not eat normally. Reduced appetite is one
of the most common contributing factors to an owner’s
decision to euthanize their dog [3]. Therefore, stimulating
appetite would aid in providing optimal nutrition for the
dog which is critical for managing many disease condi-
tions, and would be a positive sign for the veterinarian
and pet owner. Restoring optimal nutrition could help
dogs recover from surgery or injury faster by increasing
strength, immune function and wound healing. In
addition, increased appetite could possibly shorten a
hospital stay or even be a benefit by providing time so
that the dog’s underlying issue can be identified and
addressed [1, 4]. Restoring appetite is an important
component of many treatment plans for sick dogs.
Discovery of a drug that may be helpful in treating
dogs with reduced appetite began with the creation of a
new class of drugs, the growth hormone secretagogues
(GHS) - a class of small molecule compounds discovered
in the mid-1990s that stimulate the release of growth
hormone (GH) and may be useful in treatment of
anorexia and cachexia [5]. It was subsequently discove-
red that GHS compounds mimic ghrelin, the hormone
that is secreted from endocrine cells in the stomach and
stimulates appetite and food intake in humans [6].
Capromorelin is an orally active potent growth hormone
secretagogue receptor (GHS-R) agonist that mimics the
action of ghrelin and acts directly on the hunger centers
of the hypothalamus to stimulate appetite and enhance
food consumption [5]. Since there were no FDA approved
veterinary drugs for inappetence, veterinarians currently
uses unapproved alternatives that were not developed for
the purpose of appetite stimulation. Examples of un-
approved drugs used to stimulate appetite in dogs and cats
include mirtazapine, cyproheptadine, maropitant, benzo-
diazepines and glucocorticoids. The problem with many
of these unapproved alternatives is that safe and effica-
cious doses have not been established for pets. The FDA
has approved capromorelin (ENTYCE®) and this approval
represents the first regulatory approval, either veterinary
or human, of a drug with this mechanism of action, i.e. a
ghrelin receptor agonist.
Capromorelin oral solution has been shown to in-
crease food consumption, body weight and GH and
insulin-like growth factor 1 (IGF-1) secretion in a small
study in laboratory Beagle dogs [7]. A 12-month oral
safety study in adult dogs has shown that long-term
daily oral administration of capromorelin at a dose ap-
proximately 17.5 times that of the dose tested in the
present study is safe [8].
Client–owned dogs that are experiencing reduced ap-
petite due to a variety of clinical conditions may not be
as sensitive to the effects of a ghrelin receptor agonist
such as capromorelin. To confirm that capromorelin
could prove efficacious in dogs with clinical signs of in-
appetence, two masked, placebo-controlled, randomized,
multi-site clinical studies in client-owned dogs have been
conducted in veterinary clinics in the USA. First, a pilot
study was conducted in 36 dogs presenting with reduced
appetite from a variety of clinical conditions. Seven days
of treatment with capromorelin was associated with in-
creased body weight, and owner’s assessed their dogs ap-
petites were increased when compared to placebo
treated dogs [9]. In a recent clinical study in 244 dogs at
over 30 veterinary clinics, dogs experiencing inappetence
from a variety of conditions were treated with 3 mg/kg
capromorelin for 4 days. This study demonstrated a
statistically significant improvement in appetite as mea-
sured by an owner appetite assessment (P = 0.0078) and
an increase in body weight (P = 0.0004) in the capromore-
lin treated group compared to the placebo group [10].
In these clinical studies, although owners assessed
their dogs as showing an increased appetite, and dogs
gained weight, there was no direct evidence of increased
food intake, due the difficulties of measuring food intake
in a pet at home who may be fed a variety of foods by vari-
ous household members, and food intake data may also
be confounded due to multiple pets in the household.
The purpose of this laboratory study was to confirm in
a well controlled environment, where food intake could
be accurately measured, that a 3 mg/kg daily treatment
of capromorelin oral solution given for 4 days to male
and female laboratory dogs would increase food con-
sumption and body weight.
Methods
Animals and housing
Twenty-four, non-naïve healthy Beagle dogs, bred for re-
search purposes (Marshall BioResources, North Rose, NY),
were divided into 2 treatment groups (n = 6 males and 6
females/group). Dogs ranged from 13.3 to 13.8 months of
age at the study start. Body weights ranged from 6.5 to
9.4 kg for females and 10.0 to 12.6 kg for males at
randomization. Dogs were housed individually in stainless
steel cages with controlled temperature (18 to 29 °C), rela-
tive humidity ranging from 30 to 70% and a photoperiod
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of 12 h of light alternating with 12 h of darkness. All dogs
were under the care of a licensed veterinarian. Water was
provided ad libitum (see below for information about
feeding). At the end of the study (following weighing on
Day 4), all dogs were returned to the facility colony.
Treatment
The study tested capromorelin flavored oral solution
(ENTYCE®) with 30 mg/ml of capromorelin compared
to a matched placebo flavored oral solution treatment
(which contained all the ingredients of the formulation
without capromorelin) administered for 4 days. Dogs
were randomized into two groups, with Group 1 receiving
placebo (0.1 ml/kg) and Group 2 receiving 3.0 mg/kg
ENTYCE®. Both groups were treated once a day at
approximately 9 AM each day. The first day of dosing was
considered Day 0. The placebo and test drug were
administered by a syringe placed in the corner of the
mouth. The Day 0 weight was used for dose calculations.
Observations
Dogs were observed at least twice daily and any clinical or
behavioral observations were recorded. A physical exami-
nation of each dog was completed on Days -14, -2, 0 and
on Day 4 at the time of the final body weight measure-
ment. Serum chemistry and hematology (CBC) screening
to confirm the health status of each dog prior to enroll-
ment was conducted on Day -2 and repeated on Day 3,
approximately 4 to 5 h following administration of the last
dose and within 1 h after removal of food, to evaluate any
change over the 4 day treatment period. Body weights
were recorded prior to feeding on Days -14, -2, 0 and 4.
Feeding and evaluation of food consumption
Dogs were fed a 25.44% protein nutritionally complete
and balanced diet1 once daily. The dogs were placed on
a time-restricted feeding period beginning 14 days prior
to the start of the study. At approximately 10 AM
(±30 min) following an overnight fast, dogs were offered
600 grams of food (i.e., twice their normal ration) for a
total of 3 h (± 10 min), at which time any remaining
food was removed. Food was weighed prior to and after
food offering. Food consumption was recorded daily
from Day -14 through Day 3.
Masking
Individuals making any observations on the condition of
the dogs, including physical examinations, and any indi-
viduals recording data on food consumption and body
weight were masked to treatment group.
Statistical analyses
For food consumption, the baseline value was defined as
the mean of the values collected on Day -3, Day -2 and
Day -1. The treatment period was the mean of the values
collected from Day 0 through Day 3 (4 days) and the
percent change was calculated between baseline average
and the treatment period average. For body weight, the
baseline value was the value obtained at Day 0. Percent
changes from baseline were calculated at Day 4, the
treatment period for body weight.
Descriptive statistics (number of subjects, mean,
standard deviation, standard error of the mean, mini-
mum, median and maximum values) were presented for
food consumption percent change at each day measured
and body weight percent change, for the treatment
period, and baseline. All tests of significance were 2-
sided and performed at alpha = 0.05. The SAS® software
system,2 Version 9.2, was used for all calculations.
Analysis of variance (ANOVA) modeling was utilized
to evaluate differences between the treated and placebo
groups. The ANOVA model contained terms for treat-
ment, sex and the interaction of treatment by sex. When
the interaction term was statistically significant then the
treatment group comparisons were carried out for each
sex separately. Otherwise, the treatment group compari-
sons were carried out across the pooled sexes.
In addition, the treatment groups were compared by per-
mutation testing using the SAS® procedure MULTTEST.
When, in the ANOVA described above, either the treat-
ment by sex interaction or the sex main effect was signifi-
cant, the treatment groups were compared separately for
each sex. Otherwise, the treatment groups were com-
pared across the pooled sexes. Also, within treatment
group, comparisons were assessed by the one-sample t-
test or Wilcoxon signed rank test, as appropriate, to
evaluate the percent change from baseline for body
weight and food consumption. The Shapiro-Wilk test
for normality was conducted, at the 0.05 significance
level, to determine the appropriateness of the one-sam-
ple t-test. When statistically significant, the Wilcoxon
signed rank test was conducted.
Results
Clinical observations
The capromorelin and placebo oral solutions appeared
to be well tolerated. Salivation was observed repeatedly
in all dogs of the capromorelin group post-dosing during
all treatment days and in two dogs administered placebo
only once on Day 0. Emesis occurred once in two pla-
cebo treated dogs during the three days prior to treat-
ment and once in one dog of the capromorelin group
during the treatment period. All dogs were considered
healthy for the study by the physical examination com-
pleted on Day -14. No observations of concern were
noted and there were no treatment-related findings in
physical examinations performed at the end of the study.
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Serum chemistry and hematology
There were no treatment related changes in serum
chemistry or hematology parameters.
Food consumption and body weight
There were no statistically significant differences (P = 0.31)
in results for food consumption or body weight between
male and female dogs, so data were pooled. Dogs receiving
capromorelin had food consumption that was significantly
greater than dogs treated with placebo. Capromorelin
treated dogs had increased mean (±SD) food consumption
compared to placebo treated dogs (60.55 ± 39.87% versus
-11.15 ± 14.23% respectively, P < 0.001). Mean food con-
sumption for each group is presented in Fig. 1. The mean
percent changes in food consumption in each group are
presented in Table 1. All dogs in the capromorelin group
gained weight from Day 0 to Day 3. Treated dogs also
had increased mean body weights compared to placebo
treated dogs (5.96 ± 1.76% versus 0.053 ± 1.14% respectively,
P < 0.001). The mean percentage changes in body weight
for each group are presented in Table 1. The dogs treated
with capromorelin had a mean gain of 0.52 kg while the
placebo treated dogs had a mean weight gain of 0.004 kg.
Discussion
Capromorelin oral solution appeared to be well tolerated.
The salivation observed in the capromorelin group post-
dosing during all treatment days was not considered an
adverse event as it is an expected pharmacologic action of
capromorelin. Salivation can be caused by a central mech-
anism in response to the smell or taste of food, which
stimulates areas of the brain that influence both the saliv-
ary nuclei and appetite center [11]. In humans, the ghrelin
receptor has been shown to be present in the salivary
glands [12] but this has not yet been demonstrated in
dogs. Given that the emesis occurred sporadically in both
treatment groups during the acclimation and treatment
periods, this finding was considered incidental.
Laboratory dogs were initially utilized to measure the
effects of capromorelin oral solution because of the diffi-
culties of measuring food consumption in client-owned
dogs on a variety of diets. In laboratory dogs, food con-
sumption and body weight can be carefully measured so
that the effect of capromorelin could be demonstrated.
Increased food consumption in laboratory dogs confirms
data from clinical studies that show an increase in owner
assessed appetite in dogs receiving capromorelin oral
solution. Therefore, it has been established that dogs
treated with capromorelin oral solution have an in-
creased appetite which leads to increased food consump-
tion and increased body weight.
This study showed an increase in food consumption,
as expected, in the group receiving the capromorelin 4-
day treatment. The large increase in food consumption
in the capromorelin treatment group and the resulting
increase in body weight over such a short treatment
period demonstrates the robust effect of capromorelin.
These changes in food consumption and body weight
confirm results from an earlier study in laboratory dogs
[7]. In that initial laboratory study, the capromorelin
effects on food consumption and body weight were
demonstrated in a small population of Beagles that
included 6 male dogs per group. The current study in-
cluded 12 dogs, with 6 of each sex per treatment group
and had greater statistical power.
A limitation of this study is the short duration;
additional studies of longer duration will be needed to
demonstrate continued effect of daily treatment. Single
breed studies (in Beagles) also need to be confirmed in
studies of client-owned dogs.
Fig. 1 Mean (±SD) food consumption in dogs (n = 6 males and 6
females/group) treated with placebo (◊) or capromorelin (●) oral
solution. Day 0 is the first day of dosing. Capromorelin resulted in
statistically significantly greater mean food consumption as compared
to placebo (P < 0.001)
Table 1 Food consumption and body weight percent changes
in dogs treated with either placebo or capromorelin
Percent food consumption
change (Mean ± SD)
Percent weight increase
from day 0 to day 3
(Mean ± SD)
Capromorelin 60.55 ± 39.87a 5.96 ± 1.76
Placebo -11.15 ± 14.23b 0.053 ± 1.14
P value < 0.001 < 0.001
Dogs (n = 6 males, 6 females/group treated for 4 days with either placebo or
capromorelin oral solution at 3 mg/kg/day
amean increase of 117.6 grams daily
bmean decrease of 30.4 grams daily
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Conclusions
In summary, capromorelin has been demonstrated to be
effective in increasing food consumption in healthy Beagle
dogs and this increased food consumption results in
increases in body weight over four days of treatment.
The results of this study, along with confirmation that
capromorelin increases appetite and body weight in
dogs suffering from clinical inappetence, indicate that
capromorelin may be a useful new tool for the stimula-
tion of appetite.
Endnotes
1Lab Diet® 25% protein certified canine diet 5007, PMI
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